Brief: Skye Bioscience Demonstrates Over 30% Weight Loss With Nimacimab And Tirzepatide Combination In Preclinical Model
15/04/2025 13:51
April 15 (Reuters) - Eli Lilly and Co LLY.N: SKYE BIOSCIENCE DEMONSTRATES OVER 30% WEIGHT LOSS WITH NIMACIMAB AND TIRZEPATIDE COMBINATION IN PRECLINICAL MODEL SKYE BIOSCIENCE INC - NIMACIMAB SHOWS ADDITIVE WEIGHT LOSS EFFECT WITH TIRZEPATIDE IN DIO MODEL SKYE BIOSCIENCE INC - NIMACIMAB PHASE 2A TOP-LINE DATA EXPECTED LATE Q3/EARLY Q4 2025 SKYE BIOSCIENCE INC - NIMACIMAB AND TIRZEPATIDE COMBINATION SHOWS >30% WEIGHT LOSS SKYE BIOSCIENCE INC - NIMACIMAB ALONE SHOWS 23.5% WEIGHT LOSS Source text: ID:nGNX5vMw83 Further company coverage: LLY.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Skye Bioscience
See all newsBrief: Skye Announces Cohort Review Committee Approved Opening Of Cohort 2 Based On Favorable Safety Data From First Four Participants Treated In Cohort 1
U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis
U.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
U.S. STOCKS ON THE MOVE-Energy firms, Estee Lauder, HMH Holding
Skye Bioscience rises as it begins testing higher doses of obesity drug